
Sign up to save your podcasts
Or


TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Kenneth Cusi, MD, FACP, FACE, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism from The University of Florida about managing nonalcoholic fatty liver disease.
Listen in as they discuss considerations with managing nonalcoholic fatty liver disease (NAFLD)...including risk factors, screening, and treatment options.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Cusi reports relevant financial relationships with Echosens, Inventiva, Nordic Pharma, Novo Nordisk, Poxel, Zydus (grants/research support); Ionis, Janssen, Genentech, Gilead, Madrigal, Merck, Novo Nordisk, Pfizer, Poxel, Terns Pharmaceuticals (consultant). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
Claim Credit
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
By TRC Healthcare4.8
3636 ratings
TRC Editor, Dr. Lori Dickerson, PharmD, FCCP talks with Kenneth Cusi, MD, FACP, FACE, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism from The University of Florida about managing nonalcoholic fatty liver disease.
Listen in as they discuss considerations with managing nonalcoholic fatty liver disease (NAFLD)...including risk factors, screening, and treatment options.
You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:
For the purposes of disclosure, Dr. Cusi reports relevant financial relationships with Echosens, Inventiva, Nordic Pharma, Novo Nordisk, Poxel, Zydus (grants/research support); Ionis, Janssen, Genentech, Gilead, Madrigal, Merck, Novo Nordisk, Pfizer, Poxel, Terns Pharmaceuticals (consultant). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.
Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses.
Claim Credit
Send us a text
Email us: [email protected].
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.

697 Listeners

498 Listeners

106 Listeners

296 Listeners

259 Listeners

3,341 Listeners

1,149 Listeners

729 Listeners

193 Listeners

512 Listeners

428 Listeners

370 Listeners

150 Listeners

3 Listeners

6 Listeners